NASDAQ:MGNX MacroGenics - MGNX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.17 +0.05 (+0.70%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$6.99▼$7.2650-Day Range$4.82▼$7.2452-Week Range$2.13▼$10.20Volume411,307 shsAverage Volume718,636 shsMarket Capitalization$443.39 millionP/E RatioN/ADividend YieldN/APrice Target$11.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability MacroGenics MarketRank™ ForecastAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside56.2% Upside$11.20 Price TargetShort InterestBearish7.57% of Shares Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$3.33 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.56) to ($1.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector400th out of 1,004 stocksPharmaceutical Preparations Industry183rd out of 489 stocks 3.3 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Buy. The company's average rating score is 2.55, and is based on 6 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.20, MacroGenics has a forecasted upside of 56.2% from its current price of $7.17.Amount of Analyst CoverageMacroGenics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.57% of the outstanding shares of MacroGenics have been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in MacroGenics has recently increased by 5.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 1.9 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MacroGenics this week, compared to 3 articles on an average week.Search InterestOnly 16 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows7 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have bought 10,180.00% more of their company's stock than they have sold. Specifically, they have bought $3,330,000.00 in company stock and sold $32,393.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of MacroGenics is held by insiders.Percentage Held by Institutions93.63% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to decrease in the coming year, from ($0.56) to ($1.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MacroGenics (NASDAQ:MGNX) StockMacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.Read More Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comMacroGenics (NASDAQ:MGNX) Price Target Increased to $12.00 by Analysts at BTIG ResearchMarch 22, 2023 | finance.yahoo.comMacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)April 1, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.March 22, 2023 | americanbankingnews.comMacroGenics, Inc. to Post Q1 2023 Earnings of $1.20 Per Share, HC Wainwright Forecasts (NASDAQ:MGNX)March 21, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for MacroGenics (MGNX)March 21, 2023 | americanbankingnews.comGuggenheim Reiterates "Neutral" Rating for MacroGenics (NASDAQ:MGNX)March 21, 2023 | americanbankingnews.comSVB Leerink Analysts Cut Earnings Estimates for MacroGenics, Inc. (NASDAQ:MGNX)March 18, 2023 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) Q4 2022 Earnings Call TranscriptApril 1, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.March 16, 2023 | finance.yahoo.comWhy Shares of MacroGenics Climbed ThursdayMarch 15, 2023 | finance.yahoo.comMacroGenics (MGNX) Surpasses Q4 Earnings EstimatesMarch 15, 2023 | finance.yahoo.comMacroGenics (MGNX) Q4 2022 Earnings Call TranscriptMarch 15, 2023 | finance.yahoo.comMacroGenics Provides Corporate Update and 2022 Financial ResultsMarch 14, 2023 | finance.yahoo.comSynaffix Announces Expansion of ADC Collaboration with MacroGenicsMarch 11, 2023 | finance.yahoo.comAnalyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging HigherMarch 8, 2023 | finance.yahoo.comMacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 MillionMarch 7, 2023 | finance.yahoo.comMacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference CallFebruary 20, 2023 | finance.yahoo.comStrength Seen in MacroGenics (MGNX): Can Its 25.7% Jump Turn into More Strength?February 14, 2023 | finance.yahoo.comMacroGenics Posts Interim Data From Lorigerlimab Study In Prostate Cancer PatientsJanuary 6, 2023 | finance.yahoo.comMacroGenics (MGNX) Stock Sinks As Market Gains: What You Should KnowJanuary 4, 2023 | finance.yahoo.comMacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of DirectorsJanuary 4, 2023 | finance.yahoo.comMacroGenics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2023 | finance.yahoo.comInvestors in MacroGenics (NASDAQ:MGNX) from five years ago are still down 66%, even after 13% gain this past weekDecember 6, 2022 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) insider upped their holding by 26% earlier this yearDecember 5, 2022 | finance.yahoo.comCan MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?December 2, 2022 | finance.yahoo.comMacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving AverageNovember 22, 2022 | finance.yahoo.comWhy Shares of MacroGenics Were Dropping TuesdaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Company Calendar Last Earnings11/02/2021Today4/01/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees427Year Founded2000Price Target and Rating Average Stock Price Forecast$11.20 High Stock Price Forecast$17.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+56.2%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,760,000.00 Net Margins-78.82% Pretax Margin-78.82% Return on Equity-81.79% Return on Assets-49.63% Debt Debt-to-Equity RatioN/A Current Ratio4.57 Quick Ratio4.54 Sales & Book Value Annual Sales$151.94 million Price / Sales2.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book3.10Miscellaneous Outstanding Shares61,840,000Free Float56,954,000Market Cap$443.39 million OptionableOptionable Beta1.97 Social Links Key ExecutivesScott E. KoenigPresident, Chief Executive Officer & DirectorEric RisserChief Operating OfficerJames KarrelsChief Financial Officer, Secretary & Senior VPEzio BonviniChief Scientific Officer & Senior VP-ResearchStephen L. EckChief Medical Officer & SVP-Clinical DevelopmentKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXErascaNASDAQ:ERASKaryopharm TherapeuticsNASDAQ:KPTITerns PharmaceuticalsNASDAQ:TERNEdgewise TherapeuticsNASDAQ:EWTXView All CompetitorsInsiders & InstitutionsJeffrey Stuart PetersSold 5,372 sharesTotal: $32,393.16 ($6.03/share)Voya Investment Management LLCSold 13,435 shares on 2/28/2023Ownership: 0.089%Alliancebernstein L.P.Bought 12,700 shares on 2/16/2023Ownership: 0.175%Point72 Middle East FZEBought 4,148 shares on 2/16/2023Ownership: 0.007%T. Rowe Price Investment Management Inc.Sold 5,281 shares on 2/15/2023Ownership: 4.680%View All Insider TransactionsView All Institutional Transactions MGNX Stock - Frequently Asked Questions Should I buy or sell MacroGenics stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks. What is MacroGenics' stock price forecast for 2023? 11 brokers have issued 12 month price objectives for MacroGenics' stock. Their MGNX share price forecasts range from $5.00 to $17.00. On average, they predict the company's share price to reach $11.20 in the next twelve months. This suggests a possible upside of 56.2% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts. How have MGNX shares performed in 2023? MacroGenics' stock was trading at $6.71 at the beginning of 2023. Since then, MGNX stock has increased by 6.9% and is now trading at $7.17. View the best growth stocks for 2023 here. When is MacroGenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our MGNX earnings forecast. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) posted its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.23. The biopharmaceutical company had revenue of $15.66 million for the quarter, compared to the consensus estimate of $39.56 million. MacroGenics had a negative net margin of 78.82% and a negative trailing twelve-month return on equity of 81.79%. During the same quarter last year, the firm earned ($0.66) EPS. What ETFs hold MacroGenics' stock? ETFs with the largest weight of MacroGenics (NASDAQ:MGNX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco DWA SmallCap Momentum ETF (DWAS), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB) and What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC). What is MacroGenics' stock symbol? MacroGenics trades on the NASDAQ under the ticker symbol "MGNX." How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MacroGenics' stock price today? One share of MGNX stock can currently be purchased for approximately $7.17. How much money does MacroGenics make? MacroGenics (NASDAQ:MGNX) has a market capitalization of $443.39 million and generates $151.94 million in revenue each year. The biopharmaceutical company earns $-119,760,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. How many employees does MacroGenics have? The company employs 427 workers across the globe. How can I contact MacroGenics? MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321. This page (NASDAQ:MGNX) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.